Skip to main content
Premium Trial:

Request an Annual Quote

Pritzker Neuropsychiatric Disorders Research Consortium, GlaxoSmithKline, Golden Helix, UC Berkeley, GeneGo, Nycomed, Genedata, Applied Biosystems, Geneva Bioinformatics, University of Tokyo, Research Center for Advanced Science and Technology, GeneBio

Pritzker Neuropsychiatric Disorders Consortium Expands Ingenuity Deal
The Pritzker Neuropsychiatric Disorders Research Consortium has renewed and expanded its licensing agreement for access to Ingenuity Systems’ Pathways Analysis software, Ingenuity announced this week.
Consortium members will use the latest release of IPA to illustrate significant differences in gene expression and to determine impact in neuronal pathways, circuits, and target systems, Ingenuity said.
The PNDRC focuses on understanding the neurobiology and genetics of mood disorders including schizophrenia. is the group includes representatives from the University of Michigan, Weill Medical College of Cornell University, Stanford University, the University of California at Irvine, and the University of California at Davis.
More information about the alliance is available here.

GSK Renews License for Golden Helix’s Genetic-Association Software
GlaxoSmithKline has renewed its worldwide site license for Golden Helix’s HelixTree.
The software, which Golden Helix developed in 1998 with GlaxoSmithKline, uses statistical methodologies for candidate gene and whole genome-association studies designed to identify links among genetic, environmental, and clinical data.

UC Berkeley Molecular Toxicology Curriculum Expands GeneGo License
UC Berkeley will expand its use of GeneGo’s MetaCore/MetaDrug discovery platform in its computational toxicology course, the company said this week.
The course is a required component for Molecular Toxicology majors and in undergraduate honors research programs, GeneGo said. The agreement will provide students with chemical structure, network and pathway-analysis tools needed to analyze complex omics datasets and to predict and understand the beneficial and potentially harmful effects of chemicals in humans and other species.

Nycomed Extends Contract With Genedata for Screener Software
Genedata has signed a multi-year contract extension with drug maker Nycomed for the use of its Screener lead-discovery product suite, Genedata said this week.
The company said it will create a global scientific computing infrastructure for the lead discovery and drug research programs at Nycomed sites worldwide.
Genedata Screener will enable interdisciplinary teams at Nycomed to capture, visualize, analyze, and manage large volumes of assay data, the company said in a statement.
Screener is designed to support low to ultra-high-throughput screens, single-point assays, or complex high-content screens.

ABI Establishes Next-Gen Genomic Analysis Service for Scientists
Applied Biosystems has established a next-generation genomic-analysis service program based on its SOLiD next-generation sequencing platform .
Scientists may now access next generation technology through several global service providers, including Agencourt Bioscience, GATC Biotech, Seqwright DNA Sequencing, and Sistemas Genomicos.

University of Tokyo Uses GeneBio’s Phenyx Protein ID Platform
Geneva Bioinformatics and the University of Tokyo have announced that the Research Center for Advanced Science and Technology has acquired a license to GeneBio’s Phenyx. The university will use the platform in its protein-identification research, GeneBio said in a statement.
Developed in collaboration with the Swiss Institute of Bioinformatics, the Phenyx software identifies and characterizes proteins and peptides from mass spectrometry data.

Filed under

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.